Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Enterprise Value: 2023-2025

Historic Enterprise Value for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $2.4 billion.

  • CG Oncology's Enterprise Value rose 20.14% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $299.5 million, marking a year-over-year decrease of 56.15%. This contributed to the annual value of $1.2 billion for FY2024, which is 738.14% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Enterprise Value is $2.4 billion, which was up 81.03% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Enterprise Value ranged from a high of $2.4 billion in Q3 2025 and a low of -$187.7 million during Q4 2023.
  • In the last 3 years, CG Oncology's Enterprise Value had a median value of $1.4 billion in 2024 and averaged $1.5 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first surged by 738.14% in 2024, then tumbled by 50.05% in 2025.
  • Quarterly analysis of 3 years shows CG Oncology's Enterprise Value stood at -$187.7 million in 2023, then spiked by 738.14% to $1.2 billion in 2024, then rose by 20.14% to $2.4 billion in 2025.
  • Its Enterprise Value was $2.4 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.2 billion in Q1 2025.